PBAC's latest decision on Relatlimab with nivolumab: Recommended with restriction (2022). Considered for Treatment of patients with unresectable Stage III or IV malignant melanoma who have not previously received systemic anti-cancer therapy for this indication.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Adults and adolescents 12 years of age or older, weighing at least 40 kg, with unresectable Stage III or IV malignant melanoma, previously untreated with systemic anti-cancer therapy, with ECOG performance status 0 or 1, excluding uveal melanoma.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
CA224047, CA209067
Comparator
nivolumab monotherapy
Economic model
CUA
ICER note
ICER value not stated in the provided text excerpt; economic analysis details appear to be redacted or incomplete in the supplied document portion.